Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)

Epilepsy is a complex and heterogeneous neurological disorder that requires individualized management. While the market continues to rely heavily on longestablished generic antiseizure medications (AEDs), innovation is increasingly shifting toward therapies for refractory and genetically driven epilepsies. Latephase development is focused on targeted agents—such as relutrigine (Praxis), azetukalner (Xenon), carisbamate (SK Biopharmaceuticals), opakalim (Biohaven), and bexicaserin (Lundbeck)—aimed at addressing persistent gaps in difficulttotreat and orphan epilepsies. This report evaluates the market potential of these late-phase therapies, as well as potential diseasemodifying options, zorevunersen (Biogen/Stoke) and elsunersen (Praxis), gene therapies in Phase 3 development. Our forecast also considers rapidacting outpatient rescue therapies, including Staccato alprazolam. Collectively, these pipeline developments signal a transition from broad symptomatic seizure control toward more precise treatments that better meet the needs of patients with severe, refractory, or genetically defined epilepsy syndromes.

Questions answered

• How does the epilepsy market vary across regions, and how is it expected to evolve in the near future?
• What market dynamics and competitive strategies will shape the success of new and existing AEDs in an increasingly genericized landscape?
• What challenges persist in the treatment of drug-resistant epilepsy, and how are emerging therapies working to address these unmet needs?

Geography: United States, EU5, Japan.

Primary research: Country-specific interviews with thought-leading neurologists. Survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of epilepsy by country.

Market forecast features: 10-year, annualized, drug-level sales and patient share of key epilepsy therapies through 2035, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.